Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company

UCB S.A. clinical trials

The registry lists 580 studies whose lead sponsor is UCB S.A. or one of 23 companies grouped under it. 26 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Keep track of what changes. Save the UCB S.A. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

Status

Completed: 474
Terminated: 52
Recruiting: 22
Active, not recruiting: 11
Withdrawn: 11
No longer available: 5

Phase

Phase 3: 244
Phase 1: 131
Phase 2: 127
Phase 4: 43

Where

United States: 279
Germany: 214
United Kingdom: 144
Spain: 141
Poland: 135
France: 120

Focus areas

Conditions UCB S.A. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Epilepsy132 Seizures77 Parkinson Disease45 Arthritis, Rheumatoid40 Epilepsies, Partial31 Crohn Disease29 Psoriasis25 Lupus Erythematosus, Systemic20 Rhinitis, Allergic20 Arthritis, Psoriatic19 Myasthenia Gravis18 Restless Legs Syndrome17 Axial Spondyloarthritis14 Rhinitis, Allergic, Seasonal10 Spondylitis, Ankylosing10

Studies

Recruiting first, then most recently updated. Showing 50 of 580. Browse all 580 →

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisRecruitingNCT06668181Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic DiseasesRecruitingNCT07712939Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted after Candid Therapeutics became part of UCB S.A.
A Phase 3 Study of Fenfluramine Hydrochloride in Rett SyndromeRecruitingNCT07503444Phase 3
Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusRecruitingNCT06617325Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusEnrolling by invitationNCT04976322Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingNCT07463521Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic BronchitisRecruitingNCT07725939Phase 2
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingNCT07465289Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisEnrolling by invitationNCT06435312Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisRecruitingNCT06055959Phase 2/3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresRecruitingNCT05077904Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresEnrolling by invitationNCT05076617Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)RecruitingNCT06888193Phase 1
Sponsor listed in the registry: UCB Biopharma SRL
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisRecruitingNCT07246564Phase 4
Sponsor listed in the registry: UCB Biopharma SRL
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis BronchiectasisRecruitingNCT07720375Phase 2
Sponsor listed in the registry: UCB Biopharma SRL
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.
Clinical Study of Cizutamig in Systemic Lupus ErythematosusRecruitingNCT07215663Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.
A Clinical Study of Cizutamig in Thyroid Eye DiseaseRecruitingNCT07597200Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating WomenRecruitingNCT06961747Phase 1
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisRecruitingNCT07219420Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
SLC6A1-NDD Prospective Longitudinal Natural History StudyRecruitingNCT07531511
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With SeizuresRecruitingNCT04715646Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in AdultsRecruitingNCT07290036Phase 1
Sponsor listed in the registry: UCB Biopharma SRL
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))RecruitingNCT05135091Phase 3
Sponsor listed in the registry: Neurona Therapeutics · First submitted before Neurona Therapeutics became part of UCB S.A.
Doxecitine and Doxribtimine-Expanded AccessAvailableNCT06590493
Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)RecruitingNCT06422923Phase 1/2
Sponsor listed in the registry: Neurona Therapeutics · First submitted before Neurona Therapeutics became part of UCB S.A.
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisActive, not recruitingNCT06540144Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisCompletedNCT06149559Phase 2/3
Sponsor listed in the registry: UCB Biopharma SRL
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisCompletedNCT04225871Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)Active, not recruitingNCT05063162Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04901195Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.CompletedNCT07849894Phase 1
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With OsteoporosisCompletedNCT05067335Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT03895203Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
Pediatric Arthritis Study of Certolizumab PegolCompletedNCT01550003Phase 3
Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial SpondyloarthritisCompletedNCT03928704Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT03896581Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04242446Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing SpondylitisCompletedNCT03928743Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04242498Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06921850Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic DermatitisActive, not recruitingNCT07277660Phase 2
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT06425549Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromeCompletedNCT06118255Phase 3
Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group
A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy ParticipantsTerminatedNCT06555601Phase 1
Sponsor listed in the registry: UCB Biopharma SRL
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisCompletedNCT04436640Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 DeficiencyCompletedNCT03845712Phase 2
Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT04009499Phase 3
Sponsor listed in the registry: UCB Biopharma SRL
An Open-label Study of CND261 in Seropositive Rheumatoid ArthritisActive, not recruitingNCT07052032Phase 1
Sponsor listed in the registry: Candid Therapeutics · First submitted before Candid Therapeutics became part of UCB S.A.
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisCompletedNCT06624228Phase 3
Sponsor listed in the registry: UCB Biopharma SRL